Patents by Inventor Kathryn A. FRASER

Kathryn A. FRASER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20220047620
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: March 29, 2021
    Publication date: February 17, 2022
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20210283169
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: March 29, 2021
    Publication date: September 16, 2021
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20190060351
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20190060350
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • ?-glucan methods and compositions that affect the tumor microenvironment
    Patent number: 10111900
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa Sh. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
    Patent number: 10111901
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa S H. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20170100424
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20170100425
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON
  • Biological production of zeaxanthin and carotenoid biosynthesis control
    Patent number: 8361743
    Abstract: The present invention relates to the isolation of carotenoids and in particular the xanthophyll zeaxanthin (zeaxanthin-?,?-Carotene-3,3?-diol) and optionally other carotenoids such as lycopene, ?,?-carotene, 3?-hydroxyechinenone ?-cryptoxanthin and the colourless carotenoids, phytoene and phytofluene from a marine bacterium belonging to the genus Algibacter which is capable of producing the aforementioned compounds. The present invention also provides a strain of Algibacter which is capable of producing significant levels of carotenoids, especially zeaxanthin at high purity, as well as methods of using the Algibacter strain and uses of the carotenoids produced.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: January 29, 2013
    Assignee: Aquapharm Bio-Discovery Ltd.
    Inventors: Issouf Mohamed, Andrew Spragg Mearns, Kathryn Fraser, Richard Hodgson
  • Biological Production of Zeaxanthin and Carotenoid Biosynthesis Control
    Publication number: 20080293097
    Abstract: The present invention relates to the isolation of carotenoids and in particular the xanthophyll zeaxanthin (zeaxanthin-?,?-Carotene-3,3?-diol) and optionally other carotenoids such as lycopene, ?,?-carotene, 3?-hydroxyechinenone ?-cryptoxanthin and the colourless carotenoids, phytoene and phytofluene from a marine bacterium belonging to the genus Algibacter which is capable of producing the aforementioned compounds. The present invention also provides a strain of Algibacter which is capable of producing significant levels of carotenoids, especially zeaxanthin at high purity, as well as methods of using the Algibacter strain and uses of the carotenoids produced.
    Type: Application
    Filed: May 5, 2006
    Publication date: November 27, 2008
    Inventors: Issouf Mohamed, Andrew Spragg Mearns, Kathryn Fraser, Richard Hodgson